CA
NZ
UK
AU
IND
US
The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement speaking to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare and …
The Phase 2/3 designation itself reflects the transitional nature of sutacimig's current development stage: the company has completed a Phase 2 long-term extension study while simultaneously planning its registration-directed Phase 3 trial, a designation that captures both the maturity of the existing dataset and …
Private placements of this size are relatively uncommon for early clinical-stage biotech companies, and the involvement of Hansoh Pharma as a lead investor carries particular significance given that Hansoh is also the company that originally licensed AVR-001, Avere's lead drug candidate, to the business. …
Today's favorable reaction suggests that investors may have been more focused on the certainty and finalization of funding than on the incremental dilution associated with the raise. For small-cap biotech companies operating with limited cash runway, removing uncertainty about near-term financing availability can itself …
At the center of the deal is Utebzi, Spero's approved oral antibiotic currently partnered with GSK. Under the arrangement, Spero is trading away its rights to future milestone payments and net sales royalties tied to Utebzi in exchange for the $105 million in upfront …
At the center of the agreement is SP001, a Phase 2-ready anti-CD40L monoclonal antibody that Spero is in-licensing from Innovent. CD40L is a protein involved in immune cell signaling that plays a central role in numerous autoimmune and inflammatory conditions, and antibodies targeting this …
AVR-001's defining engineering feature is its approximately 100-hour half-life, which enables once-weekly oral administration. Achieving this kind of metabolic stability in a cyclic peptide is a notable technical accomplishment, as peptides have historically struggled to achieve the durability needed for infrequent oral dosing given …
The combined company will be guided by CEO Dr. Andrew Cheng and will prioritize AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist licensed from Hansoh Pharma. Reverse mergers of this kind allow private companies like Avere to gain public market access by combining with …
Redwire Corp (NYSE: RDW) disclosed that its board has welcomed Gregory L. Heston as a new director. The decision, recommended by the Nominating and Corporate Governance Committee, follows the earlier departure of David Kornblatt.
PayPal Holdings Inc. (NASDAQ: PYPL) is at the center of a proposed acquisition by Stripe and Advent International. The joint proposal fixes the purchase price at $60.50 per share, a valuation that lifts the payment processor above $53 billion. Early trading data shows the …
Please wait processing your request...